Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Local immune effector cell-associated toxicity syndrome in CAR T-cell treated patients with autoimmune disease: an observational study

1 May 2025

Abstract excerpt

BACKGROUND: CD19-targeting chimeric antigen receptor (CAR) T-cell therapy has advanced treatment strategies for severe autoimmune diseases such as systemic lupus erythematosus (SLE), systemic sclerosis, and idiopathic inflammatory myopathy. Data regarding side-effects are mostly generated from patients with malignancies, but little is known about autoimmune disease-specific adverse events. This study aimed to...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to CAR-T cell therapy research
Share to Cutaneous lymphoproliferative disorders research
Share to Inflammatory Myopathies and Dermatomyositis

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Source

Identifiers

PMID: 40318690
DOI: 10.1016/s2665-9913(25)00091-8

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 11 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Local immune effector cell-associated toxicity syndrome in CAR T-cell treated patients with autoimmune disease: an observational studyPMID 40318690Read ↗

Inflammatory arthritis immune related adverse events represent a unique autoimmune disease entity primarily driven by T cells, but likely not autoantibodiesSemantic proximity Read ↗

Overview of Adverse Events Associated With Anti-CD19 Chimeric Antigen Receptor T-Cell TherapySemantic proximity Read ↗

Immune effector cell-associated haematotoxicity after CAR T-cell therapy: from mechanism to managementSemantic proximity Read ↗

CAR-T AND autoimmune diseases in nervous systemSemantic proximity Read ↗

Comparison of the safety profiles of CD19-targeting CAR T-cell therapy in patients with SLE and B-cell lymphomaSemantic proximity Read ↗

Thyroid-related Adverse Events Caused by Immune Checkpoint Inhibitors Associated with Therapeutic Outcomes in Cancer Patients: a systematic review and meta-analysisSemantic proximity Read ↗

Clonally-Expanded, Thyrotoxic Autoimmune Mediator CD8 <sup>+</sup> T cells Driven by IL21 Contribute to Checkpoint Inhibitor ThyroiditisSemantic proximity Read ↗

Brexucabtagene Autoleucel For Relapsed/Refractory Mantle Cell Lymphoma in Asia: Redefining the Role of Allogeneic Haematopoietic Stem Cell TransplantationSemantic proximity Read ↗

CAR-T Cell Therapy: Mechanism, Management, and Mitigation of Inflammatory Toxicities.Semantic proximity Read ↗

Comparative real-world outcomes of CD19-directed CAR T-cell therapies in large B-cell lymphomaSemantic proximity Read ↗

Cytopenias following anti-CD19 chimeric antigen receptor (CAR) T cell therapy: a systematic analysis for contributing factorsSemantic proximity Read ↗

Hepatic Failure Associated with Immune Checkpoint Inhibitors: A Real-world Study from the Food and Drug Administration Adverse Event Reporting System (FAERS) DatabaseSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.